Macrophage Plasticity and Polarization Are Altered in the Experimental Model of Multiple Sclerosis

Alessandro Leuti1,2, Emanuela Talamonti3, Antonietta Gentile4

  • 1Department of Medicine, Campus Bio-Medico University of Rome, 00128 Rome, Italy.

Biomolecules
|July 2, 2021
PubMed

Insights

In multiple sclerosis (MS), pro-inflammatory M1 macrophages become hyperactivated, while anti-inflammatory M2 macrophages shift towards a pro-inflammatory state. This imbalance in macrophage phenotypes is crucial for understanding MS immunopathology.

Area of Science:

  • Neuroimmunology
  • Cellular Immunology

Background:

  • Multiple sclerosis (MS) is an immune-mediated central nervous system disease involving leukocyte infiltration.
  • Macrophages are key effectors in MS and its animal model, experimental autoimmune encephalomyelitis (EAE), but their activation and heterogeneity remain poorly understood.

Purpose of the Study:

  • To investigate the immunophenotype and balance of M1 and M2 macrophages in EAE.
  • To analyze phenotypic alterations in macrophages during the course of experimental autoimmune encephalomyelitis.

Main Methods:

  • Polychromatic flow cytometry, qRT-PCR, and ELISA were used to analyze over 30 surface and intracellular markers on M1 and M2 macrophages from EAE and control mice.
  • Macrophage phenotypes were assessed after immunization with MOG35-55.

Main Results:

  • M1 macrophages exhibited a heightened pro-inflammatory profile in EAE, with increased expression of activation markers (iNOS, CD40, CD80) and cytokines/chemokines (IL-6, IL-12, CCL2, CXCL10).
  • M2 macrophages lost their anti-inflammatory phenotype, showing decreased expression of signature markers (CD206, CCL22) and upregulation of M1 markers.
  • Macrophage immunization with MOG35-55 resulted in M1 hyperactivation and a shift of M2 to M1 phenotypes.

Conclusions:

  • A significant alteration in the M1/M2 macrophage balance occurs during experimental autoimmune encephalomyelitis.
  • These findings are vital for understanding MS immunopathology and developing novel macrophage-targeted therapies.

Related Concept Videos